GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Fusen Pharmaceutical Co 1652.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.95

—

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Fusen Pharmaceutical Co

Its shares trade on HKEX under the ticker 1652.HK. It has been listed since 11 July 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥273.4m and a net loss of CN¥11.8m. At that date it held total assets of CN¥1.26bn and shareholders' equity of CN¥359.4m.

Fusen Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceuticals and medical devices. The company is headquartered in Nanyang, Henan. The company went IPO on 2018-07-11. The firm is mainly engaged in research, development, production and sales of Chinese patent drugs and western medicine products for the treatment of cold and fever, cardiovascular diseases and anemia. The firm's main products include small volume injections, oral liquids, tablets, capsules and granules. The firm distributes its products mainly in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
11 Jul 2018
Employees
1,121
Website
fusenyy.com ↗

Leadership

Pay as last reported

  • Mr. Zhiming CaoExecutive Chairman of the Board, Chief Executive Officer, since 2013CN¥2.0m
  • Mr. Zhen LiChief Financial Officer
  • Mr. Jiancheng FuVice President, since 2017CN¥93,000
  • Mr. Yongsheng ChiExecutive Director, since 2017CN¥70,000
  • Mr. Taisheng HouExecutive Director, since 2017CN¥70,000
  • Ms. Qingfen MengExecutive Director, since 2017CN¥69,000
  • Mr. Yuk Hong YeungCompany Secretary
  • Mr. Kwok Tung LeeNon-Executive Independent DirectorCN¥149,000
  • Mr. Wing Chun SzeNon-Executive Independent DirectorCN¥149,000
  • Dr. Kit Wa ToIndependent Non-Executive DirectorCN¥149,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Fusen Pharmaceutical employs 1,121 full-time employees in Nanyang, Henan.
  • Fusen focuses on research, development, production, and sales of Chinese patent drugs.
  • Fusen distributes products mainly in the domestic market within China.

Weaknesses

  • Fusen's products include small volume injections and oral liquids for cold and fever treatment.
  • Fusen's main products are limited to tablets, capsules, and granules.
  • Fusen's business is concentrated in the domestic market of China.

Opportunities

  • Fusen's research in cardiovascular disease treatments offers growth potential.
  • Fusen's focus on anemia treatments presents new market opportunities.
  • Fusen's production of western medicine products can expand internationally.

Threats

  • Fusen faces competition from other pharmaceutical companies in China.
  • Fusen's reliance on domestic market distribution poses risks.
  • Fusen's product range is limited to specific medical conditions.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.